![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Warns Chinese API Supplier for Deficient COAs, Quality
FDA Warns Chinese API Supplier for Deficient COAs, Quality
September 10, 2019
The FDA issued a warning letter to an active pharmaceutical ingredient distributor in Chongqing southwestern China for serious problems with quality and certificates of analysis.
The agency inspected Yino’s facility from March 18-22 and found significant GMP violations for APIs it relabeled and distributed to other facilities for eventual sale in the U.S. Specifically, the COAs it generated for multiple lots of injectable-grade drugs lacked the name and address of the original manufacturer.
In addition, COAs the firm created for several lots of API didn’t include a signature and date from an authorized quality unit employee.
Upcoming Events
-
21Oct